Addex Therapeutics logo

Addex Therapeutics share price today

(ADXN)

Addex Therapeutics share price is $7.98 & ₹684.76 as on 7 Jan 2025, 2.30 'hrs' IST

$7.98

-0.39

(-4.66%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Addex Therapeutics share price in Dollar and Rupees. Guide to invest in Addex Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Addex Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Addex Therapeutics share price movements

  • Today's Low: $7.98
    Today's High: $8.93

    Day's Volatility :10.64%

  • 52 Weeks Low: $6.00
    52 Weeks High: $27.90

    52 Weeks Volatility :78.49%

Addex Therapeutics Returns

PeriodAddex Therapeutics LtdIndex (Russel 2000)
3 Months
-19.05%
0.0%
6 Months
0.84%
0.0%
1 Year
6.62%
0.0%
3 Years
-93.41%
-19.8%

Addex Therapeutics Key Statistics

in dollars & INR

Previous Close
$8.37
Open
$8.93
Today's High
$8.93
Today's Low
$7.98
Market Capitalization
$8.1M
Today's Volume
$8.0K
52 Week High
$27.9
52 Week Low
$6.0
Revenue TTM
$863.2K
EBITDA
$-11.1M
Earnings Per Share (EPS)
$-21.25
Profit Margin
500.17%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-126.29%

How to invest in Addex Therapeutics from India?

It is very easy for Indian residents to invest directly in Addex Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Addex Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Addex Therapeutics or ADXN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Addex Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Addex Therapeutics shares which would translate to 0.108 fractional shares of Addex Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Addex Therapeutics, in just a few clicks!

Returns in Addex Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Addex Therapeutics investment value today

Current value as on today

₹1,04,879

Returns

₹4,879

(+4.88%)

Returns from Addex Therapeutics Stock

₹1,656 (+1.66%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Addex Therapeutics

50%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Addex Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 50% more investors are searching Addex Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Addex Therapeutics

  • ADAR1 Capital Management LLC

    0.09%

  • Morgan Stanley - Brokerage Accounts

    0.03%

Analyst Recommendation on Addex Therapeutics

Sell

    10%Buy

    20%Hold

    70%Sell

Based on 10 Wall street analysts offering stock ratings for Addex Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
2
3
3
Sell
7
7
7

Analyst Forecast on Addex Therapeutics

What analysts predicted

Upside of 275.94%

Current:

$7.98

Target:

$30.00

Insights on Addex Therapeutics

  • Price Movement

    In the last 3 years, ADXN stock has moved down by -93.3%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 234.91K → 53.83K (in $), with an average decrease of 52.1% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 12.87M → -1.52M (in $), with an average decrease of 111.9% per quarter
  • ADXN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 3.0%
  • ADXN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 148.5%
  • Price to Sales

    ForADXN every $1 of sales, investors are willing to pay $7.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Addex Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$6.1M
↑ 1109.03%
Net Income
$-1.7M
↓ 49.86%
Net Profit Margin
-27.21%
↑ 629.01%
FY19Y/Y Change
Revenue
$2.8M
↓ 54.29%
Net Income
$-15.0M
↑ 798.63%
Net Profit Margin
-534.98%
↓ 507.77%
FY20Y/Y Change
Revenue
$4.1M
↑ 30.77%
Net Income
$-14.5M
↓ 13.0%
Net Profit Margin
-355.92%
↑ 179.06%
FY21Y/Y Change
Revenue
$3.2M
↓ 19.28%
Net Income
$-16.7M
↑ 19.39%
Net Profit Margin
-526.42%
↓ 170.5%
FY22Y/Y Change
Revenue
$1.5M
↓ 51.22%
Net Income
$-22.3M
↑ 35.52%
Net Profit Margin
-1.5K%
↓ 936.15%
FY23Y/Y Change
Revenue
$1.9M
↑ 13.39%
Net Income
$-12.2M
↓ 49.26%
Net Profit Margin
-654.47%
↑ 808.1%
Q2 FY23Q/Q Change
Revenue
$363.9K
↓ 48.05%
Net Income
$-2.9M
↓ 2.17%
Net Profit Margin
-798.54%
↓ 374.5%
Q3 FY23Q/Q Change
Revenue
$170.8K
↓ 53.18%
Net Income
$-3.2M
↑ 9.16%
Net Profit Margin
-1.9K%
↓ 1063.19%
Q4 FY23Q/Q Change
Revenue
$177.5K
↑ 0.0%
Net Income
$-3.3M
↑ 0.0%
Net Profit Margin
-1.9K%
↑ 0.0%
Q1 FY24Q/Q Change
Revenue
$264.3K
↑ 53.08%
Net Income
$-3.5M
↑ 8.06%
Net Profit Margin
-1.3K%
↑ 547.55%
Q2 FY24Q/Q Change
Revenue
$129.0K
↓ 50.93%
Net Income
$14.4M
↓ 517.17%
Net Profit Margin
11.2K%
↑ 12486.08%
Q3 FY24Q/Q Change
Revenue
$53.8K
↓ 53.3%
Net Income
$-1.5M
↓ 111.88%
Net Profit Margin
-2.8K%
↓ 14013.76%
FY18Y/Y Change
Profit
$5.9M
↑ 1154.91%
FY19Y/Y Change
Profit
$2.6M
↓ 57.07%
FY20Y/Y Change
Profit
$-7.6M
↓ 366.92%
FY21Y/Y Change
Profit
$-10.8M
↑ 46.47%
FY22Y/Y Change
Profit
$-14.1M
↑ 33.31%
FY23Y/Y Change
Profit
$-6.2M
↓ 59.68%
Q2 FY23Q/Q Change
Profit
$-1.6M
↑ 19.14%
Q3 FY23Q/Q Change
Profit
$-1.6M
↓ 6.03%
Q1 FY24Q/Q Change
Profit
$264.4K
-
Q2 FY24Q/Q Change
Profit
$129.0K
↓ 50.95%
Q3 FY24Q/Q Change
Profit
$53.8K
↓ 53.3%
FY18Y/Y Change
Operating Cash Flow
$1.8M
↓ 182.05%
Investing Cash Flow
$-56.8K
↑ 7987.66%
Financing Cash Flow
$37.7M
↑ 1014.47%
FY19Y/Y Change
Operating Cash Flow
$-9.6M
↓ 641.3%
Investing Cash Flow
$-44.0K
↓ 23.27%
Financing Cash Flow
$-471.7K
↓ 101.24%
FY20Y/Y Change
Operating Cash Flow
$-13.7M
↑ 28.45%
Investing Cash Flow
$-66.8K
↑ 37.36%
Financing Cash Flow
$52.2K
↓ 110.01%
FY21Y/Y Change
Operating Cash Flow
$-16.0M
↑ 20.73%
Investing Cash Flow
$-32.9K
↓ 48.98%
Financing Cash Flow
$17.8M
↑ 35251.67%
FY22Y/Y Change
Operating Cash Flow
$-17.6M
↑ 11.78%
Investing Cash Flow
$3.2K
↓ 109.8%
Financing Cash Flow
$3.3M
↓ 81.08%
Q2 FY23Q/Q Change
Operating Cash Flow
$-2.5M
↓ 18.34%
Investing Cash Flow
$-2.8K
↑ 0.0%
Financing Cash Flow
$-209.8K
↓ 104.21%

Addex Therapeutics Technicals Summary

Sell

Neutral

Buy

Addex Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Addex Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Addex Therapeutics Ltd
7.03%
0.84%
6.62%
-93.41%
-97.11%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Addex Therapeutics Ltd
NA
NA
NA
0.0
-1.26
-0.62
NA
0.01
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Addex Therapeutics Ltd
Sell
$8.1M
-97.11%
NA
500.17%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Addex Therapeutics

addex therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. the company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including g-protein coupled receptors (gpcrs), receptor tyrosine kinases (rtks) and cytokine receptors, such as the tnf receptor superfamily. many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery. the company’s two lead products are: dipraglurant (adx48621), an mglur5 negative allosteric modulator, or nam, which reduced parkinson’s disease levodopa-induced dyskinesia (pd-lid) in a phase ii
Organization
Addex Therapeutics
Employees
23
CEO
Mr. Timothy Mark Dyer
Industry
Health Technology

Management People of Addex Therapeutics

NameTitle
Mr. Timothy Mark Dyer
Co-Founder, CEO & Director
Dr. Roger G. Mills M.D.
Chief Medical Officer & Director
Mr. Lénaic Teyssédou
Head of Finance
Dr. Mikhail Kalinichev Ph.D.
Head of Translational Science

Important FAQs about investing in Addex Therapeutics from India :

What is Addex Therapeutics share price today?

Addex Therapeutics share price today stands at $7.98, Open: $8.93 ; Previous Close: $8.37 ; High: $8.93 ; Low: $7.98 ; 52 Week High: $27.90 ; 52 Week Low: $6.00. The stock opens at $8.93, after a previous close of $8.37. The stock reached a daily high of $8.93 and a low of $7.98, with a 52-week high of $27.90 and a 52-week low of $6.00.

Can Indians buy Addex Therapeutics shares?

Yes, Indians can invest in the Addex Therapeutics (ADXN) from India.

With INDmoney, you can buy Addex Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Addex Therapeutics at zero transaction cost.

How can I buy Addex Therapeutics shares from India?

It is very easy to buy Addex Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Addex Therapeutics be purchased?

Yes, you can buy fractional shares of Addex Therapeutics with INDmoney app.

What are the documents required to start investing in Addex Therapeutics stocks?

To start investing in Addex Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Addex Therapeutics

Today’s highest price of Addex Therapeutics (ADXN) is $8.93.

Today’s lowest price of Addex Therapeutics (ADXN) is $7.98.

What is today's market capitalisation of Addex Therapeutics

Today's market capitalisation of Addex Therapeutics ADXN is 8.1M

What is the 52 Week High and Low Range of Addex Therapeutics

  • 52 Week High

    $27.90

  • 52 Week Low

    $6.00

What are the historical returns of Addex Therapeutics?

  • 1 Month Returns

    7.03%

  • 3 Months Returns

    0.84%

  • 1 Year Returns

    6.62%

  • 5 Years Returns

    -97.11%

Who is the Chief Executive Officer (CEO) of Addex Therapeutics

Mr. Timothy Mark Dyer is the current Chief Executive Officer (CEO) of Addex Therapeutics.